Showing results (11-20 of 34) with videos related to
Sort By:
Pageof 4
Iscience|November 11, 2025
TGFβ signaling in cancer-associated fibroblasts drives a hepatic gp130-dependent pro-metastatic inflammatory program in colorectal cancerTom J Harryvan, Subinuer Abudukelimu, Imke Stouten, et al.Cancer Immunology, Immunotherapy : CII|March 25, 2011
Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alphaEls M E Verdegaal, Marten Visser, Tamara H Ramwadhdoebé, et al.Molecular Therapy. Oncology|August 12, 2025
DNA-demethylation by DAC induces MAGE expression and MAGE-specific T cell reactivity against tumors but also healthy cell subsetsMarije A J de Rooij, Miranda H Meeuwsen, Anne K Wouters, et al.Pigment Cell & Melanoma Research|April 18, 2013
Genome-wide promoter methylation analysis identifies epigenetic silencing of MAPK13 in primary cutaneous melanomaLinda Gao, Marjon A Smit, Joost J van den Oord, et al.Cancer Immunology Research|January 12, 2017
Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune SignatureSara M Melief, Valeria V Visconti, Marten Visser, et al.Cancer Immunology Research|January 9, 2024
Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell-Based ImmunotherapiesChristianne Groeneveldt, Priscilla Kinderman, Lisa Griffioen, et al.Journal for Immunotherapy of Cancer|February 15, 2023
CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burdenJitske van den Bulk, Manon van der Ploeg, Marieke E Ijsselsteijn, et al.Journal for Immunotherapy of Cancer|November 10, 2023
Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancerEls M E Verdegaal, Saskia J Santegoets, Marij J P Welters, et al.BMJ Open|November 25, 2020
Phase I/II study protocol to assess safety and efficacy of adoptive cell therapy with anti-PD-1 plus low-dose pegylated-interferon-alpha in patients with metastatic melanoma refractory to standard of care treatments: the ACTME trialMonique K van der Kooij, Els M E Verdegaal, Marten Visser, et al.Nature Medicine|December 23, 2014
High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanomaCarsten Linnemann, Marit M van Buuren, Laura Bies, et al.Pageof 4